ABUS (Arbutus Biopharma) Kacepetan wutah bathi saben saham ing taun lumaku

ABUS (Tekmira Pharmaceuticals) - tandha merek perusahaan

Stable royalties from lipid nanoparticle patents create the financial foundation for Arbutus Biopharma (ABUS). The history of annual net income per share growth clearly demonstrates the impact of these licensing streams, and 538.00 captures the magnitude of this parameter. This trend is supported by the company's authority in hepatitis B treatment and a strict refusal of mergers in favor of protecting intellectual property.

ABUS (Arbutus Biopharma Corporation) riwayat Wutah bathi ing taun lumaku saka 04.07.2022 nganti 15.11.2026

Rincian metrik keuangan lan pasar Arbutus Biopharma Corporation (ABUS)

- rega saham lan konsensus proyeksi valuasi:
Bagan rega Arbutus|ABUS - Prakiraan konsensus analis
- indikator valuasi pasar bisnis:
Nilai pasar Arbutus Biopharma Corporation|ABUS - Nilai Total Perusahaan
- data ekuitas miturut neraca:
Nilai Akuntansi Saham Arbutus Biopharma|ABUS - Kapitalisasi Buku|Rasio Kapitalisasi Pasar marang Nilai Buku arbutusbio.com|ABUS - Aset Agregat Perusahaan
- rincian utang lan likuiditas:
Rasio Kabeh Utang marang Dana Pribadi Arbutus Biopharma|ABUS - Utang jangka dawa marang modal|Utang jangka cendhak marang ekuitas Arbutus|ABUS - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku Arbutus Biopharma Corp|ABUS - Kewajiban jangka dawa perusahaan|Gedhene kewajiban jangka cendhak Arbutus Biopharma|Rasio cepet arbutusbio.com
- indikator pendapatan resik lan kelipatan nilai:
ABUS - Bathi resik perusahaan|Prakiraan bathi perusahaan Arbutus Biopharma|ABUS - Koefisien rega marang bathi|Pangali mangsa ngarep rega marang bathi Arbutus Biopharma|ABUS - Pangali PEG|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Arbutus Biopharma|ABUS - Bathi operasional EBITDA|Bathi resik saben saham sajrone patang kuartal pungkasan Arbutus Biopharma|ABUS - Bathi saben saham sajrone rolas wulan pungkasan|Wutah bathi saben saham ing petungan tahunan sajrone rolas wulan pungkasan arbutusbio.com|ABUS - Wutah bathi saben saham ing taun lumaku|Prakiraan owah-owahan bathi resik saben saham kanggo taun ngarep Arbutus Biopharma
- informasi babagan volume dodolan lan pendapatan:
ABUS - Pendapatan lan volume dodolan|Pendapatan mangsa ngarep perusahaan Arbutus|ABUS - Multiplikator P/S|Multiplikator Forward P/S Arbutus Biopharma Corporation|ABUS - Wutah dodolan YoY sajrone rolas wulan kepungkur
Ringkesan analisis perusahaan:Arbutus Biopharma
Produk sing diprodhuksi arbutusbio.com

Investors assess an asset's financial stability through the annual growth rate of earnings per share, which determines the efficiency of business capitalization. For Arbutus Biopharma (ABUS) and its scalable Hepatitis B therapy model, the current value of 538.00 in the history of annual net income per share dynamics reflects a transition from the cost-intensive R&D stage to a potentially high-margin drug commercialization phase.

Pesaing wigati

ARWR (Arrowhead Pharmaceuticals Inc) - Wutah bathi saben saham ing taun lumaku|MIRM (Mirum Pharmaceuticals, Inc.) - Wutah bathi ing taun lumaku|Kacepetan wutah bathi saben saham ing taun lumaku Dynavax Technologies Corporation DVAX|Wutah bathi ing taun lumaku IVA|GYRE (Gyre Therapeutics) - Tambahing bathi saben saham ing taun lumaku|Wutah bathi ing taun lumaku ASMB (Assembly Bio)|Owah-owahan bathi resik saben saham ing taun lumaku Galectin|Genfit Corp - Wutah bathi ing taun lumaku|DRRX - Wutah bathi ing taun lumaku|ALGS: Wutah bathi ing taun lumaku|Kacepetan wutah bathi saben saham ing taun lumaku BioVie Inc. (BIVI)|Wutah bathi saben saham ing taun lumaku galmedpharma.com|NDRA: Tambahing bathi saben saham ing taun lumaku|Wutah bathi saben saham ing taun lumaku Hepion Pharmaceuticals (HEPA)